We examined whether increased CKD screening resulted in improvement in CKD quality metrics, specifically angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and sodium-glucose cotransporter 2 inhibitor (SGLT2i) use. Here, SLC5A2 is linked to chronic kidney disease.